Anavex Life Sciences Corp (AVXL)

[nidan7500]

They are basically saying..."we are clueless". Someone should send them the last MOA CELLS paper and splain a little bout ERP's.

Aducanumab Alzheimer's Prevention Trial
Aisen, Paul S. Johnson, Keith A. Langbaum, Jessica Brooke Reiman, Eric Michael Sperling, Reisa A. Tariot, Pierre N.
Banner Health, Phoenix, AZ, United States

However, if the Phase 3 program does not show significant benefit, the stakes would be even higher for our trial, since the question would remain whether intervention before clinical stages of AD is necessary to attain benefit. We would modify the trial by using the Preclinical Alzheimer Composite Endpoint-Revised (PACC-R) as the primary outcome and continuing blinded treatment until the last participant?s 48-month visit, clarify whether the treatment?s 24 month biomarker effects are associated with subsequent cognitive benefit, and seek to achieve our goals by 2025. Regardless of the Phase 3 results, the proposed trial offers an unprecedented chance to find, approve and support the availability of prevention therapies as soon as possible. It would capitalize on a public-private partnership, NIH support, $5-10M in philanthropy, access to aducanumab and most of the financial support from Biogen, provide a public resource of data and samples, and have the maximum public benefit.